Poland· PL-100491874
Ubretid
A distigmine product containing distigmini bromidum, registered in Poland by InPharm Sp. z o.o.. The same ATC class is registered in 7 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Distigmine is registered in 7 of 19 countries.
Countries holding a registration under ATC N07AA03 (distigmine), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 3 of them publish a price we can compare per daily dose
Distigmine · ATC N07AA03
7 / 19 countries
- Czechiaprice
- Finlandprice
- Germany
- Japan
- Netherlands
- Polandprice
- United Kingdom
The record
At a glance
URPL (Poland)- Active substance
- Distigmini bromidum
- Manufacturer
- InPharm Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- N07AA03
- ATC class
- Distigmine
- Defined daily dose
- 5 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909991528799
- gtin05909991528805
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Distigmine in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaUBRETIDCHEPLAPHARM Arzneimittel GmbH, Greifswald
- United KingdomDistigmine bromide 5mg tabletsSpecial Order
- NetherlandsUbretid 5 mg tablettenEuro Registratie Collectief B.V.
- FinlandUbretidNycomed Austria GmbH
- GermanyUbretidCheplapharm Arzneimittel Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- Czechia · Ubretid
- Germany · Ubretid
- Netherlands · Ubretid
- Slovakia · Ubretid
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/31d64a6b-49eb-4cb3-a021-41d40a0237c5 GET /v1/drugs/31d64a6b-49eb-4cb3-a021-41d40a0237c5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki",
"source": "urpl",
"strength": "5 mg",
"packaging": "05909991528799 ¦ Rp ¦ 152708\n20 tabl.\n05909991528805 ¦ Rp ¦ 152709\n50 tabl.",
"substance": "Distigmini bromidum 5 mg",
"common_name": "Distigmini bromidum",
"pl_product_id": "100491874",
"pozwolenie_nr": "308/23",
"auth_procedure": "IR",
"authorisation_validity": "2028-12-22"
}See everything about distigmine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.